{"id":523126,"date":"2021-12-31T14:54:44","date_gmt":"2021-12-31T19:54:44","guid":{"rendered":"https:\/\/goldtadise.com\/?p=523126"},"modified":"2021-12-31T14:56:16","modified_gmt":"2021-12-31T19:56:16","slug":"non-white-new-yorkers-to-receive-priority-for-scarce-life-saving-covid-pill","status":"publish","type":"post","link":"https:\/\/goldtadise.com\/?p=523126","title":{"rendered":"Non-White New Yorkers To Receive Priority For Scarce Life-Saving COVID Pill"},"content":{"rendered":"<p><em>&#8220;This policy is\u00a0<strong>blatant racism<\/strong>&#8230;&#8221;<\/em><\/p>\n<p>&#8220;NYSDOH said the newly authorized oral antiviral treatments, including Paxlovid (Pfizer) and molnupiravir (Merck), are in &#8220;limited supply will require providers to\u00a0<strong>prioritize treatment for patients at highest risk for severe COVID-19<\/strong>\u00a0until more product becomes available.&#8221;<\/p>\n<p>The department\u00a0<strong>prioritizes those who are severely immunocompromised<\/strong>\u00a0or have at least one risk factor for severe illness can receive oral antiviral treatments. Besides some risk factors that include cancer, diabetes, dementia, and or other debilitating diseases, the\u00a0<strong>NYSDOH list being non-white &#8220;should be considered a risk factor<\/strong>, as long-standing systemic health and social inequities have contributed to an increased risk of severe illness and death from Covid-19.&#8221;<\/p>\n<p><a href=\"https:\/\/www.zerohedge.com\/markets\/non-white-new-yorkers-receive-priority-scarce-covid-pill\">https:\/\/www.zerohedge.com\/markets\/non-white-new-yorkers-receive-priority-scarce-covid-pill<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;This policy is\u00a0blatant racism&#8230;&#8221; &#8220;NYSDOH said the newly authorized oral antiviral treatments, including Paxlovid (Pfizer) and molnupiravir (Merck), are in &#8220;limited supply will require providers to\u00a0prioritize treatment for patients at highest risk for severe COVID-19\u00a0until more product becomes available.&#8221; The &hellip; <a href=\"https:\/\/goldtadise.com\/?p=523126\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":2948,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-523126","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/goldtadise.com\/index.php?rest_route=\/wp\/v2\/posts\/523126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/goldtadise.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/goldtadise.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/goldtadise.com\/index.php?rest_route=\/wp\/v2\/users\/2948"}],"replies":[{"embeddable":true,"href":"https:\/\/goldtadise.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=523126"}],"version-history":[{"count":0,"href":"https:\/\/goldtadise.com\/index.php?rest_route=\/wp\/v2\/posts\/523126\/revisions"}],"wp:attachment":[{"href":"https:\/\/goldtadise.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=523126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/goldtadise.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=523126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/goldtadise.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=523126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}